Ipsens Onivyde Pancreatic Cancer Trial Survival Disappointment Dashes Sales Boost Hopes

Merely Matches FOLFIRINOX OS

 
• By Ayisha Sharma

The French firm unveiled data from its pancreatic cancer trial showing Onivyde plus chemotherapy improved median PFS by just over a month compared with current treatment of choice but failed to beat its overall survival benchmark.  

Two pairs of hands playing tug of war with rope against blue sky background
The Overall Survival Tug-Of-War Has Ended In A Draw • Source: Shutterstock

More from Clinical Trials

More from R&D